Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks
IntroductionA rapid increase in COVID-19 cases due to the spread of the Delta and Omicron variants in vaccinated populations has raised concerns about the hospitalization risk associated with, and the effectiveness of, COVID-19 vaccines.MethodThis case–control study aims to determine the hospitaliza...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1049393/full |
| _version_ | 1811165223733690368 |
|---|---|
| author | Mohammed Albreiki Mira Mousa Mira Mousa Syafiq Kamarul Azman Hema Vurivi Zainab Alhalwachi Fatima Alshehhi Safiya AlShamsi Nada Al Marzouqi Tayba Alawadi Hussain Alrand Abderrahim Oulhaj Abderrahim Oulhaj Asma Fikri Asma Fikri Asma Fikri Habiba Alsafar Habiba Alsafar Habiba Alsafar Habiba Alsafar |
| author_facet | Mohammed Albreiki Mira Mousa Mira Mousa Syafiq Kamarul Azman Hema Vurivi Zainab Alhalwachi Fatima Alshehhi Safiya AlShamsi Nada Al Marzouqi Tayba Alawadi Hussain Alrand Abderrahim Oulhaj Abderrahim Oulhaj Asma Fikri Asma Fikri Asma Fikri Habiba Alsafar Habiba Alsafar Habiba Alsafar Habiba Alsafar |
| author_sort | Mohammed Albreiki |
| collection | DOAJ |
| description | IntroductionA rapid increase in COVID-19 cases due to the spread of the Delta and Omicron variants in vaccinated populations has raised concerns about the hospitalization risk associated with, and the effectiveness of, COVID-19 vaccines.MethodThis case–control study aims to determine the hospitalization risk associated with the inactivated BBIBP-CorV (Sinopharm) and mRNA BNT162b2 (Pfizer–BionTech) vaccines, and their effectiveness reducing the rate of hospital admission between 28 May 2021 and 13 January 2022, during the Delta and Omicron outbreaks. The estimation of vaccine effectiveness of 4,618 samples was based on the number of patients hospitalized at different vaccination statuses, adjusted for confounding variables.ResultsHospitalization risk increases in patients affected with the Omicron variant if patients are aged ≤ 18 years (OR 6.41, 95% CI 2.90 to 14.17; p < 0.001), and in patients affected with the Delta variant if they are aged > 45 years (OR 3.41, 95% CI 2.21 to 5.50; p < 0.001). Vaccine effectiveness reducing the rate of hospital admission for fully vaccinated participants infected with the Delta and Omicron variants was similar for both the BBIBP-CorV (94%, 95% CI 90% to 97%; 90%, 95% CI 74% to 96%) and BNT162b2 vaccines (95%, 95% CI 61% to 99.3%; 94%, 95% CI 53% to 99%), respectively.DiscussionThe BBIBP-CorV and BNT162b2 vaccines utilized in the UAE vaccination program were highly effective in reducing the rate of COVID-19-related hospitalization during the Delta and Omicron outbreaks, and further effort must be taken to achieve high vaccine coverage rates in children and adolescents in the global context to reduce the hospitalization risk associated with COVID-19 on an international scale. |
| first_indexed | 2024-04-10T15:33:47Z |
| format | Article |
| id | doaj.art-c7f232c829da4962a3e43b663b8abfdb |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T15:33:47Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-c7f232c829da4962a3e43b663b8abfdb2023-02-13T11:01:22ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-02-011410.3389/fimmu.2023.10493931049393Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaksMohammed Albreiki0Mira Mousa1Mira Mousa2Syafiq Kamarul Azman3Hema Vurivi4Zainab Alhalwachi5Fatima Alshehhi6Safiya AlShamsi7Nada Al Marzouqi8Tayba Alawadi9Hussain Alrand10Abderrahim Oulhaj11Abderrahim Oulhaj12Asma Fikri13Asma Fikri14Asma Fikri15Habiba Alsafar16Habiba Alsafar17Habiba Alsafar18Habiba Alsafar19Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab EmiratesCenter for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab EmiratesNuffield Department of Women’s and Reproduction Health, Oxford University, Oxford, United KingdomDepartment of Electrical Engineering and Computer Science, Khalifa University of Science and Technology, Abu Dhabi, United Arab EmiratesCenter for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab EmiratesCenter for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab EmiratesPublic Health Sector, Ministry of Health and Prevention, Dubai, United Arab EmiratesNational Center for Health Research, Ministry of Health and Prevention, Dubai, United Arab EmiratesPublic Health Sector, Ministry of Health and Prevention, Dubai, United Arab EmiratesPublic Health Sector, Ministry of Health and Prevention, Dubai, United Arab EmiratesPublic Health Sector, Ministry of Health and Prevention, Dubai, United Arab EmiratesCollege of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab EmiratesResearch and Data Intelligence Support Center, Khalifa University, Abu Dhabi, United Arab EmiratesNational Center for Health Research, Ministry of Health and Prevention, Dubai, United Arab EmiratesFaculty of Medicine, University of Sharjah, Sharjah, United Arab EmiratesEmirates Health Services Establishment, Dubai, United Arab EmiratesCenter for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates0Department of Biomedical Engineering, College of Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates1Department of Genetics and Molecular Biology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates2Emirates Bio-Research Center, Ministry of Interior, Abu Dhabi, United Arab EmiratesIntroductionA rapid increase in COVID-19 cases due to the spread of the Delta and Omicron variants in vaccinated populations has raised concerns about the hospitalization risk associated with, and the effectiveness of, COVID-19 vaccines.MethodThis case–control study aims to determine the hospitalization risk associated with the inactivated BBIBP-CorV (Sinopharm) and mRNA BNT162b2 (Pfizer–BionTech) vaccines, and their effectiveness reducing the rate of hospital admission between 28 May 2021 and 13 January 2022, during the Delta and Omicron outbreaks. The estimation of vaccine effectiveness of 4,618 samples was based on the number of patients hospitalized at different vaccination statuses, adjusted for confounding variables.ResultsHospitalization risk increases in patients affected with the Omicron variant if patients are aged ≤ 18 years (OR 6.41, 95% CI 2.90 to 14.17; p < 0.001), and in patients affected with the Delta variant if they are aged > 45 years (OR 3.41, 95% CI 2.21 to 5.50; p < 0.001). Vaccine effectiveness reducing the rate of hospital admission for fully vaccinated participants infected with the Delta and Omicron variants was similar for both the BBIBP-CorV (94%, 95% CI 90% to 97%; 90%, 95% CI 74% to 96%) and BNT162b2 vaccines (95%, 95% CI 61% to 99.3%; 94%, 95% CI 53% to 99%), respectively.DiscussionThe BBIBP-CorV and BNT162b2 vaccines utilized in the UAE vaccination program were highly effective in reducing the rate of COVID-19-related hospitalization during the Delta and Omicron outbreaks, and further effort must be taken to achieve high vaccine coverage rates in children and adolescents in the global context to reduce the hospitalization risk associated with COVID-19 on an international scale.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1049393/fullCOVID-19SARS-CoV-2hospitalizationDeltaOmicronUAE |
| spellingShingle | Mohammed Albreiki Mira Mousa Mira Mousa Syafiq Kamarul Azman Hema Vurivi Zainab Alhalwachi Fatima Alshehhi Safiya AlShamsi Nada Al Marzouqi Tayba Alawadi Hussain Alrand Abderrahim Oulhaj Abderrahim Oulhaj Asma Fikri Asma Fikri Asma Fikri Habiba Alsafar Habiba Alsafar Habiba Alsafar Habiba Alsafar Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks Frontiers in Immunology COVID-19 SARS-CoV-2 hospitalization Delta Omicron UAE |
| title | Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks |
| title_full | Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks |
| title_fullStr | Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks |
| title_full_unstemmed | Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks |
| title_short | Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks |
| title_sort | risk of hospitalization and vaccine effectiveness among covid 19 patients in the uae during the delta and omicron outbreaks |
| topic | COVID-19 SARS-CoV-2 hospitalization Delta Omicron UAE |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1049393/full |
| work_keys_str_mv | AT mohammedalbreiki riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT miramousa riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT miramousa riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT syafiqkamarulazman riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT hemavurivi riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT zainabalhalwachi riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT fatimaalshehhi riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT safiyaalshamsi riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT nadaalmarzouqi riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT taybaalawadi riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT hussainalrand riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT abderrahimoulhaj riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT abderrahimoulhaj riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT asmafikri riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT asmafikri riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT asmafikri riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT habibaalsafar riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT habibaalsafar riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT habibaalsafar riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks AT habibaalsafar riskofhospitalizationandvaccineeffectivenessamongcovid19patientsintheuaeduringthedeltaandomicronoutbreaks |